VE
Venus Remedies Ltd (VENUSREM)
₹1,796.70
Mkt cap
₹2,115 Cr
P/E ratio
18.20
P/B
3.62
Div yield
0.63%
ROE
16.80%
ROCE
21.70%
EPS (TTM)
₹98.72
Book value
₹497
52W range
428–2,044
Sector
Healthcare
Price history
Previous close
Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}
NSE VENUSREMBSE 526953
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBullish
52-week range
−12.11% from high₹1,797
₹428+319.79% from low₹2,044
Current
₹1,796.70
Prev close
₹1,796.10
Day
+0.03%
Price performance
1D
+0.50%
1W
+11.09%
1M
+12.75%
3M
+4.89%
6M
+120.11%
1Y
+301.24%
YTD
+130.46%
Financials
Revenue, profit & margin
P/E ratio
18.2×
VENUSREM is 47% below the sector median of 34.6×
VENUSREM18.2×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 | |
| Expenses | 85 | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 | |
| Operating Profit | 10 | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 | |
| OPM % | 11% | 11% | 8% | 10% | 10% | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% | |
| Other Income | 2 | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | |
| Profit before tax | 5 | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 | |
| Tax % | 77% | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% | |
| Net Profit | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 | |
| EPS in Rs | 0.88 | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202641.76%Promoter
Promoters41.76%
FIIs2.92%0.12
DIIs0.89%0.31
Public54.44%0.20
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Venus Remedies | ₹1,582.20 | 18.20 | 2,115 | 0.63% | 23 | +139.27% | 179 | +30.38% | 21.67% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Credit ratings4
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Sep - Newspaper publication of shareholder notice on Transfer of physical shares.Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Sep - Newspaper publication for shareholders awareness on transfer of physical shares.Social Media Post On Shareholders Awareness On Transfer Of Physical Shares. 8 Sep - Social media notice on special window for re-lodgement of physical share transfer requests.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 21 Aug - 37th AGM resolutions passed, including Rs.10 final dividend and director appointments.Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 21 Aug - Shareholders approved MOA/AOA alteration at 20 Aug 2026 AGM.